Literature DB >> 29533784

NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma.

Alexandra Garancher1, Charles Y Lin2, Morgane Morabito1, Wilfrid Richer3, Nathalie Rocques1, Magalie Larcher1, Laure Bihannic4, Kyle Smith5, Catherine Miquel6, Sophie Leboucher7, Nirmitha I Herath1, Fanny Dupuy1, Pascale Varlet8, Christine Haberler9, Christine Walczak10, Nadine El Tayara10, Andreas Volk10, Stéphanie Puget11, François Doz12, Olivier Delattre13, Sabine Druillennec1, Olivier Ayrault1, Robert J Wechsler-Reya14, Alain Eychène1, Franck Bourdeaut15, Paul A Northcott16, Celio Pouponnot17.   

Abstract

Cancer cells often express differentiation programs unrelated to their tissue of origin, although the contribution of these aberrant phenotypes to malignancy is poorly understood. An aggressive subgroup of medulloblastoma, a malignant pediatric brain tumor of the cerebellum, expresses a photoreceptor differentiation program normally expressed in the retina. We establish that two photoreceptor-specific transcription factors, NRL and CRX, are master regulators of this program and are required for tumor maintenance in this subgroup. Beyond photoreceptor lineage genes, we identify BCL-XL as a key transcriptional target of NRL and provide evidence substantiating anti-BCL therapy as a rational treatment opportunity for select MB patients. Our results highlight the utility of studying aberrant differentiation programs in cancer and their potential as selective therapeutic vulnerabilities.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCL2; CRX; MAF; NRL; apoptosis; medulloblastoma; photoreceptor; retina

Mesh:

Substances:

Year:  2018        PMID: 29533784      PMCID: PMC6368680          DOI: 10.1016/j.ccell.2018.02.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  21 in total

1.  Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy.

Authors:  Anand Maurya; Upendra Kumar Patel; Jitendra Kumar Yadav; Virender Pratap Singh; Alka Agarwal
Journal:  Methods Mol Biol       Date:  2022

2.  Unified rhombic lip origins of group 3 and group 4 medulloblastoma.

Authors:  Kyle S Smith; Laure Bihannic; Brian L Gudenas; Parthiv Haldipur; Ran Tao; Qingsong Gao; Yiran Li; Kimberly A Aldinger; Igor Y Iskusnykh; Victor V Chizhikov; Matthew Scoggins; Silu Zhang; Angela Edwards; Mei Deng; Ian A Glass; Lynne M Overman; Jake Millman; Alexandria H Sjoboen; Jennifer Hadley; Joseph Golser; Kshitij Mankad; Heather Sheppard; Arzu Onar-Thomas; Amar Gajjar; Giles W Robinson; Volker Hovestadt; Brent A Orr; Zoltán Patay; Kathleen J Millen; Paul A Northcott
Journal:  Nature       Date:  2022-09-21       Impact factor: 69.504

3.  Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.

Authors:  Meng Li; Yujie Han; Chaochen Wang; Wenfeng Kang; Wenyan Jiang; Lei Zhang; Yujie Tang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-22

4.  Interaction of human CRX and NRL in live HEK293T cells measured using fluorescence resonance energy transfer (FRET).

Authors:  Xinming Zhuo; Barry E Knox
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

5.  An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate.

Authors:  Jamie Zagozewski; Ghazaleh M Shahriary; Ludivine Coudière Morrison; Olivier Saulnier; Margaret Stromecki; Agnes Fresnoza; Gareth Palidwor; Christopher J Porter; Antoine Forget; Olivier Ayrault; Cynthia Hawkins; Jennifer A Chan; Maria C Vladoiu; Lakshmikirupa Sundaresan; Janilyn Arsenio; Michael D Taylor; Vijay Ramaswamy; Tamra E Werbowetski-Ogilvie
Journal:  Nat Commun       Date:  2020-07-20       Impact factor: 14.919

Review 6.  Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.

Authors:  Otília Menyhárt; Felice Giangaspero; Balázs Győrffy
Journal:  J Hematol Oncol       Date:  2019-03-15       Impact factor: 17.388

7.  Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.

Authors:  Yann Cormerais; Marina Pagnuzzi-Boncompagni; Sandra Schrötter; Sandy Giuliano; Eric Tambutté; Hitoshi Endou; Michael F Wempe; Gilles Pagès; Jacques Pouysségur; Vincent Picco
Journal:  J Cell Mol Med       Date:  2019-02-19       Impact factor: 5.310

Review 8.  Super-enhancer-mediated core regulatory circuitry in human cancer.

Authors:  Yuan Jiang; Yan-Yi Jiang; De-Chen Lin
Journal:  Comput Struct Biotechnol J       Date:  2021-05-05       Impact factor: 7.271

9.  Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.

Authors:  Kent A Riemondy; Sujatha Venkataraman; Nicholas Willard; Anandani Nellan; Bridget Sanford; Andrea M Griesinger; Vladimir Amani; Siddhartha Mitra; Todd C Hankinson; Michael H Handler; Martin Sill; Jennifer Ocasio; Seth J Weir; Daniel S Malawsky; Timothy R Gershon; Alexandra Garancher; Robert J Wechsler-Reya; Jay R Hesselberth; Nicholas K Foreman; Andrew M Donson; Rajeev Vibhakar
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029

10.  Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation.

Authors:  Heyu Song; Shaoyan Xi; Yingling Chen; Suravi Pramanik; Jiping Zeng; Shrabasti Roychoudhury; Hannah Harris; Anum Akbar; Salma S Elhag; Donald W Coulter; Sutapa Ray; Kishor K Bhakat
Journal:  Cancer Lett       Date:  2021-07-14       Impact factor: 9.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.